What Researchers Did
Researchers designed and tested a new multiplace plateau hyperbaric chamber at 355-, 2880-, and 4532-m high altitudes to assess its performance for acute mountain sickness treatment.
What They Found
The chamber achieved minimum pressures of 0.029, 0.022, and 0.02 MPa at 355-, 2880-, and 4532-m altitudes, respectively, with no air leaks during pressurization. Pressure equilibration between compartments ranged from 30.3±2.01 to 200.5±5.44 seconds, indicating the chamber's safe and convenient application for acute mountain sickness treatment.
Canadian Relevance
This study has no direct Canadian connection as it focuses on the development of a hyperbaric chamber for high-altitude sickness, a condition not typically prevalent in Canada's major population centers.
Study Limitations
A key limitation is the need for further testing with animals and humans to refine the hardware and establish effective utilization conditions for the chamber at high altitudes.